Literature DB >> 32453902

Comment on "Chilblains-like lesions in children following suspected COVID-19 infection".

Beuy Joob1, Viroj Wiwanitkit2,3.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32453902      PMCID: PMC7283832          DOI: 10.1111/pde.14238

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.997


× No keyword cloud information.
The publication entitled “Chilblains‐like lesions in children following suspected Covid‐19 infection” is very interesting. Colonna et al reported four children with suspected COVID‐19 cases noting that “[h]istology from one case showed signs of vasculitis with evident fibrin thrombus”. While various skin findings have been reported with COVID‐19 infection, the chilblains lesions have been reported from Italy and Spain, and sporadically from China, the starting point of disease pandemic. , , , However, it should be noted that chilblains‐like lesions have not been reported from endemic areas in tropical regions (such as Southeast Asia and South America). For example, in our country, Thailand, we have not seen any patients presenting with this skin finding despite having over 3000 cases reported as of May 11, 2020. The rarity of chilblains‐like lesions in tropical countries suggests the importance of weather, particularly cold exposure, as a possible co‐factor for this vasculopathy noted in association with COVID‐19 infection. Pathophysiologically, chilblains can result from an excessive abnormal vascular response to cold that leads to cutaneous inflammation.
  5 in total

1.  [Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia].

Authors:  Y Zhang; W Cao; M Xiao; Y J Li; Y Yang; J Zhao; X Zhou; W Jiang; Y Q Zhao; S Y Zhang; T S Li
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-03-28

2.  Comment on "Characterization of acute acro-ischemic lesions in non-hospitalized patients: A case series of 132 patients during the COVID-19 outbreak".

Authors:  Diego Fernandez-Nieto; Juan Jimenez-Cauhe; Ana Suarez-Valle; Oscar M Moreno-Arrones; David Saceda-Corralo; Arantxa Arana-Raja; Daniel Ortega-Quijano
Journal:  J Am Acad Dermatol       Date:  2020-06-01       Impact factor: 11.527

3.  Reply to: "Various forms of skin rash in COVID-19: Petechial rash in a patient with COVID-19 infection".

Authors:  Beuy Joob; Viroj Wiwanitkit
Journal:  J Am Acad Dermatol       Date:  2020-04-10       Impact factor: 11.527

4.  Chilblain-like lesions in children following suspected COVID-19 infection.

Authors:  Cristiana Colonna; Nicola Adriano Monzani; Alessia Rocchi; Raffaele Gianotti; Francesca Boggio; Carlo Gelmetti
Journal:  Pediatr Dermatol       Date:  2020-06-01       Impact factor: 1.997

5.  COVID-19 can present with a rash and be mistaken for dengue.

Authors:  Beuy Joob; Viroj Wiwanitkit
Journal:  J Am Acad Dermatol       Date:  2020-03-22       Impact factor: 15.487

  5 in total
  5 in total

1.  Chilblain and Acral Purpuric Lesions in COVID-19.

Authors:  V Wiwanitkit
Journal:  Actas Dermosifiliogr       Date:  2020-07-21

2.  Chilblain and Acral Purpuric Lesions in COVID-19.

Authors:  V Wiwanitkit
Journal:  Actas Dermosifiliogr (Engl Ed)       Date:  2020-06-19

3.  Acral lesions in a pediatric population during the COVID-19 pandemic: a case series of 36 patients from a single hospital in Spain.

Authors:  Pau Rosés-Gibert; Javier Gimeno Castillo; Amaia Saenz Aguirre; Francisco Javier De la Torre Gomar; Lucía Carnero González; Zuriñe Martinez de Lagrán Alvarez de Arcaya; Ricardo Gonzalez-Perez
Journal:  World J Pediatr       Date:  2020-09-08       Impact factor: 2.764

4.  Chilblain-like eruption in COVID-19 disease: possible pathogenetic role of temperature.

Authors:  Charlene Wee; Hong Liang Tey
Journal:  Eur J Dermatol       Date:  2020-12-01       Impact factor: 3.328

Review 5.  A dermatologic perspective on multisystem inflammatory syndrome in children.

Authors:  Fludiona Naka; Laura Melnick; Mark Gorelik; Kimberly D Morel
Journal:  Clin Dermatol       Date:  2020-11-26       Impact factor: 3.541

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.